0
There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > Licensing > BBS21003

Anti-PD-L1 / TIGIT bispecific antibody

Discovery
Preclinical
IND
PH1
PH2
PH3
BLA Filing
Active
  • Project profile
    Project name: Anti-PD-L1 / TIGIT bispecific antibody
    Indications: NSCLC, SCLC, multiple myeloma, liver cancer, triple negative breast cancer, pancreatic cancer, etc.
    Research phase: Cell line was confirmed, and cell line stability study was completed. The pilot production and toxicology study is being started.
    Cooperation demands: Project authorization, transfer or co-development.
  • Highlights
    1.Bispecific antibodies targeting both TIGIT and PD-L1 have not yet been launched around the world.
    2.The study in vivo showed that the asset has extremely significant inhibitory effect on tumor growth,which is better than PD-L1 mAb and the combination of TIGIT and PD-L1 mAb.
    3.High expression. The highest expression level was around 6g/L.
    4.Simple process. The purity of one-step affinity can reach more than 95%.
    5.Excellent stability. It remained stable for 21 days at 40℃.
    6.The indication is broad-spectrum tumor, and the market is huge.
  • Project Introduction

    1. Drug type: Bispecific antibody

    2. Mechanism:It can synergistically block the inhibitory function of TIGIT and PD-L1 immune checkpoints and produce synergistic effects.

    3. Research phase:Cell line was confirmed, and cell line stability study was completed. The pilot production and toxicology study is being started.

    5. Research progress:
    a)High yield cell lines have been obtained and cell line stability evaluation has been completed;
    b)Efficacy study in vivo and in vitro of the asset have been confirmed;
    c)High-yield monoclonal cell line has been determined, the upstream and downstream process routes have been cleared and verified;
    d)The stability study of prescription has been completed, and will enter the pilot trial stage.

Comments (0)